Viridian Therapeutics Quarterly Income Statement
NASDAQ: VRDNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Viridian Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Viridian Therapeutics generated $284,000 in revenue, up 278.7% from the same quarter a year earlier. Viridian Therapeutics reported a net loss of $127.1 million, compared with a loss of $100.7 million a year earlier. Operating margin was -44460.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Viridian Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 284.00K | 141.00K | 132.00K | 70.57M | 75.00K | 72.00K | 72.00K | 86.00K | 72.00K | 72.00K | 72.00K | 72.00K |
| Revenue growth (YoY) | +278.67% | +95.83% | +83.33% | +81958.14% | +4.17% | 0.00% | 0.00% | +19.44% | 0.00% | -26.53% | -31.43% | -93.97% |
| Operating Expenses | 126.55M | 116.31M | 122.88M | 110.58M | 106.84M | 93.94M | 87.54M | 83.57M | 72.26M | 55.97M | 71.55M | 51.30M |
| Research & Development | 71.58M | 77.63M | 89.21M | 86.26M | 86.63M | 76.83M | 71.96M | 69.16M | 56.19M | 40.94M | 38.56M | 30.39M |
| Selling, General & Admin | 54.98M | 38.68M | — | — | 20.22M | 17.10M | — | — | — | — | — | — |
| Operating Income | -126.27M | -116.17M | -122.75M | -40.01M | -106.77M | -93.87M | -87.47M | -83.48M | -72.19M | -55.90M | -71.48M | -51.22M |
| Interest Expense | 8.31M | 3.46M | 3.28M | 560.00K | 514.00K | 550.00K | 517.00K | 529.00K | 597.00K | 587.00K | 400.00K | 600.00K |
| Other Income (Expense) | -851.00K | 11.27M | 2.39M | 5.41M | 6.03M | 6.95M | 7.75M | 6.79M | 7.19M | 7.36M | 4.62M | 3.56M |
| Net Income | -127.12M | -104.90M | -120.36M | -34.60M | -100.73M | -86.91M | -79.72M | -76.69M | -64.99M | -48.54M | -66.86M | -47.66M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | — | — | — | — | — | — | -1.15 | -1.02 | -0.79 | -1.34 | -1.09 |
| EPS (Diluted) | — | — | — | — | — | — | — | -1.15 | -1.02 | -0.79 | -1.34 | -1.09 |
| Shares Outstanding (Basic) | — | — | — | — | — | — | — | 66.42M | 63.85M | 61.10M | — | 43.65M |
| Shares Outstanding (Diluted) | — | — | — | — | 81.59M | 81.34M | — | 66.42M | 63.85M | 61.10M | — | 43.65M |
| EBITDA | -126.15M | -116.05M | -122.63M | -39.90M | -106.65M | -93.75M | -87.35M | -83.35M | -72.05M | -55.75M | -71.33M | -51.09M |
| Operating Margin | -44460.56% | -82389.36% | -92991.67% | -56.70% | -142356.00% | -130369.44% | -121488.89% | -97069.77% | -100259.72% | -77634.72% | -99275.00% | -71144.44% |
| Net Margin | -44760.21% | -74397.87% | -91178.03% | -49.03% | -134313.33% | -120711.11% | -110729.17% | -89173.26% | -90268.06% | -67419.44% | -92861.11% | -66194.44% |
This table shows 12 quarterly periods of Viridian Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 18 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow VRDN's reporting calendar. What is a income statement?